Find Nonprofit and Small Business Grants

Advance Search

Only Available for Paid Subscribers
Clear Filters
Search Filters

Grants to USA, Canada, and International Clinicians and Researchers for Studies Related to Cognitive Disorders

ELIGIBILITY:

Geographic Focus

USA: AlabamaAlaskaArizonaArkansasCaliforniaColoradoConnecticutDelawareFloridaGeorgiaHawaiiIdahoIllinoisIndianaIowaKansasKentuckyLouisianaMaineMarylandMassachusettsMichiganMinnesotaMississippiMissouriMontanaNebraskaNevadaNew HampshireNew JerseyNew MexicoNew York CityNew YorkNorth CarolinaNorth DakotaOhioOklahomaOregonPennsylvaniaRhode IslandSouth CarolinaSouth DakotaTennesseeTexasUtahVermontVirginiaWashington, DCWashingtonWest VirginiaWisconsinWyoming

USA Territories: American Samoa (USA)Guam (USA)Puerto Rico (USA)Virgin Islands (USA)Northern Mariana Islands (USA)

USA Compact Free Associations: The Federated States of Micronesia (USA)  Marshall Islands (USA)  Republic of Palau (USA)

Canada: AlbertaBritish ColumbiaManitobaNew BrunswickNewfoundland and LabradorNorthwest TerritoriesNova ScotiaNunavutOntarioPrince Edward IslandQuebecSaskatchewanYukon

GrantRegions Object ( [regions] => Array ( ) [is_initialized] => [error_messages] => Array ( ) [qm] => QueryManager Object ( [is_debug] => [conn] => mysqli Object ( [affected_rows] => 9 [client_info] => mysqlnd 5.0.12-dev - 20150407 - $Id: 3591daad22de08524295e1bd073aceeff11e6579 $ [client_version] => 50012 [connect_errno] => 0 [connect_error] => [errno] => 0 [error] => [error_list] => Array ( ) [field_count] => 2 [host_info] => 172.16.38.157 via TCP/IP [info] => [insert_id] => 0 [server_info] => 5.5.5-10.5.18-MariaDB [server_version] => 100518 [stat] => Uptime: 3105723 Threads: 256 Questions: 531017147 Slow queries: 1306 Opens: 118365 Open tables: 405 Queries per second avg: 170.980 [sqlstate] => 00000 [protocol_version] => 10 [thread_id] => 86193931 [warning_count] => 0 ) ) [has_regions] => 1 [state_names] => Array ( [0] => Alabama; [1] => Alaska; [2] => Arizona; [3] => Arkansas; [4] => California; [5] => Colorado; [6] => Connecticut; [7] => Delaware; [8] => Florida; [9] => Georgia; [10] => Hawaii; [11] => Idaho; [12] => Illinois; [13] => Indiana; [14] => Iowa; [15] => Kansas; [16] => Kentucky; [17] => Louisiana; [18] => Maine; [19] => Maryland; [20] => Massachusetts; [21] => Michigan; [22] => Minnesota; [23] => Mississippi; [24] => Missouri; [25] => Montana; [26] => Nebraska; [27] => Nevada; [28] => New Hampshire; [29] => New Jersey; [30] => New Mexico; [31] => New York; [32] => North Carolina; [33] => North Dakota; [34] => New York City; [35] => Ohio; [36] => Oklahoma; [37] => Oregon; [38] => Pennsylvania; [39] => Rhode Island; [40] => South Carolina; [41] => South Dakota; [42] => Tennessee; [43] => Texas; [44] => Utah; [45] => Vermont; [46] => Virginia; [47] => Washington; [48] => Washington, DC; [49] => West Virginia; [50] => Wisconsin; [51] => Wyoming; ) [province_names] => Array ( [0] => Alberta; [1] => British Columbia; [2] => Manitoba; [3] => New Brunswick; [4] => Newfoundland and Labrador; [5] => Northwest Territories; [6] => Nova Scotia; [7] => Nunavut; [8] => Ontario; [9] => Prince Edward Island; [10] => Quebec; [11] => Saskatchewan; [12] => Yukon; ) [country_names] => Array ( [1] => American Samoa (USA) [2] => The Federated States of Micronesia (USA) [3] => Guam (USA) [4] => Marshall Islands (USA) [5] => Puerto Rico (USA) [6] => Republic of Palau (USA) [7] => Virgin Islands (USA) [8] => Northern Mariana Islands (USA) ) [is_israel] => 1 [territories] => Array ( [0] => American Samoa (USA); [1] => Guam (USA); [2] => Puerto Rico (USA); [3] => Virgin Islands (USA); [4] => Northern Mariana Islands (USA); ) [free_associations] => Array ( [0] => The Federated States of Micronesia (USA) [1] => Marshall Islands (USA) [2] => Republic of Palau (USA) ) )

Israel

International country outside of the USA, Israel and Canada.

Treat FTD Fund

Alzheimer's Drug Discovery Foundation (ADDF)

Grant Provider's 990

Agency: Foundation

GrantWatch ID #193663

Grant Description

Grants to USA, Canada, and International researchers and clinicians at IHEs, nonprofit and for-profit organizations, and academic medical centers for research related to cognitive disorders. Applicants must submit a Letter of Intent prior to submitting a full proposal. Funding is intended to address the challenges related to frontotemporal dementia (FTD), build on emerging scientific understanding of biological mechanisms underlying FTD, provide critical funding for early-stage clinical trials, and stimulate the field to develop new therapies for FTD disorders.

The Treat FTD fund aims to support programs testing drugs or devices for FTD disorders while building clinical data around FTD mechanisms in human disease and corresponding biomarker endpoints in response to treatment. The fund aims to de-risk clinical development programs by supporting clinical trials generating data leading to clear go/no-go decisions and if positive, sufficient data to encourage follow on funding of the approach. Programs will be considered that test novel or repurposed drug candidates or devices in phase 0, 1 or 2 clinical trials for FTD disorders, led by academic researchers or biotechnology companies, worldwide. Both disease-modifying and symptomatic approaches will be considered.

The RFP seeks to support clinical trials with:

  • Biological mechanisms that have a sound scientific rationale for FTD
  • Suitable clinical trial designs, that may include features such as basket trials, adaptive study designs or other novel approaches
  • Biomarkers that can indicate target engagement and/or downstream pharmacologic effects
  • Biomarker endpoints that can provide a deeper understanding of the drug mechanism and disease progression
  • Therapeutics applicable to both sporadic and genetic forms of FTD

Although the strongest proposals will contain all of these aspects, any approaches with a sound biological rationale and well-justified outcome measures for the patient population will be considered.

Funding Priorities:

  • Clinical Stage: Funding can support phase 0, 1 or 2 studies. This includes single ascending dose (SAD) and multiple ascending dose (MAD) studies to establish safety, brain penetration or target engagement in healthy subjects and/or patients. It also includes exploratory phase 1b or phase 2a trials designed to assess pharmacologic effects with shorter treatment durations and fewer patients than a traditional phase 2 study. These types of studies can serve as an important proof-of-principle to justify larger phase 2 clinical trials. Smaller studies that address one critical question or can further de-risk a clinical program will be considered. Studies that don’t align with any of these descriptions but fit the goals of the fund are also eligible.
  • Patient Population: Can include both genetic or sporadic forms of any FTD disorder, including behavioral variant FTD, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, and FTD/ALS, as well as healthy individuals for phase 1 studies or asymptomatic individuals at risk for developing FTD. 
  • Hypothesized therapeutic mechanism or mode of action: The strongest proposals will provide a clear rationale for targeting the proposed mode or mechanism of action in FTD disorders, compelling evidence that demonstrates a link to FTD, supportive preclinical data, and where available, human data.

Proposals without an identified target will also be considered but a clear connection to FTD should be described. Biological areas of interest include, but are not limited to:

  • Genetic causes of disease (C9Orf72, MAPT, GRN, etc.)
  • Misfolded proteins (TDP-43, tau, FUS, etc.)
  • Inflammation
  • Autophagy
  • Mitochondrial & metabolic function
  • Epigenetics
  • Neuroprotection
  • Synaptic activity & Neurotransmitters
  • Other novel targets or pathways that are supported by compelling evidence that demonstrate a rational biological connection to the disease process are encouraged.

The drug should have completed or be in the process of completing IND-enabling studies at the time of application. If IND-enabling work is in progress, any award would be contingent upon getting an IND from the FDA and a full review of the data package. 

Need help writing this grant?

Eligibility:

  • Others (see text field entitled "Additional Eligibility Criteria" for clarification)

Additional Eligibility Criteria:

Funding is open to researchers and clinicians worldwide at:
- Academic medical centers, universities, or non-profits. Industry partnerships are encouraged.
- Biotechnology companies. Existing companies and new startups are both eligible.
- Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.

Applications are encouraged worldwide. Any applications from outside the U.S. would be expected to meet the country or regionally-specific regulatory equivalent.

Pre-Application Information:

Deadlines:
Letter of Intent: January 27th, 2023
Full Proposal: March 17th, 2023

Applicants will first submit a letter of intent (LOI) that includes brief information about the proposed mechanism or mode of action, the drug, supporting data, biomarkers and proposed clinical trial features. The top LOIs will be invited to submit a full proposal that includes a clinical trial protocol, budget, team bio sketches, and business documents, if applicable. Applicants may expect to receive recommended revisions to their workplan or clinical trial design as part of the review process. In some circumstances, applicants may be offered access to a consultant with industry experience.

Applicants are encouraged to contact program staff to discuss the proposed clinical trial and receive initial feedback.

Application instructions: https://www.alzdiscovery.org/research-and-grants/funding-opportunities/the-treat-ftd-fund/the-treat-ftd-fund-application-instructions

Additional Funding Information:

Estimated Size of Grant:

Up to $2,000,000 based on stage and scope of the trial. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and patient enrollment.

Contact Information:

Apply online: https://addf.fluxx.io/user_sessions/new

For scientific inquiries, please contact:
Meriel Owen, PhD, Assistant Director, ADDF
mowen@alzdiscovery.org

Debra Niehoff, PhD, Research Manager, AFTD
dniehoff@theaftd.org

For policies, contracts and terms, and IT related inquiries, please contact:
Grants and Mission-Related Investments Team
grants@alzdiscovery.org

Alzheimer's Drug Discovery Foundation
57 West 57th Street, Suite 904
New York, NY 10019
info@alzdiscovery.org
212.901.8000

Live Chat Chat Now